David C. Smith
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 79
- Cancer Immunotherapy and Biomarkers 18
- Cancer Treatment and Pharmacology 16
- Cancer survivorship and care 14
-
- Prostate Cancer Treatment and Research 46
- Co-authors
- Kenneth J. Pienta (29 shared papers)Maha Hussain (27 shared papers)Marcus D. Ballinger (2 shared papers)Daniel S. Chen (2 shared papers)Keunchil Park (2 shared papers)Achim Rittmeyer (2 shared papers)Louis Fehrenbacher (2 shared papers)Julien Mazières (2 shared papers)
- Journals
- Journal of Clinical Oncology (27 papers)Cancer Chemotherapy and Pharmacology (18 papers)Cancer (15 papers)Investigational New Drugs (13 papers)Annals of Oncology (10 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
David C. Smith
343 papers receiving 36.1k citations
David C. Smith's Hit Papers
Peers
Comparison fields: 5 of 210
- Oncology 18.7k
- Immunology 7.6k
- Cancer Research 4.6k
- Pulmonary and Respiratory Medicine 9.6k
- Pathology and Forensic Medicine 1.8k
Countries citing papers authored by David C. Smith
This map shows the geographic impact of David C. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Smith more than expected).
Fields of papers citing papers by David C. Smith
This network shows the impact of papers produced by David C. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Smith. The network helps show where David C. Smith may publish in the future.
Co-authors
The 25 scholars most cited alongside David C. Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 358 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Hit paper breakdown → | 2012 | 10591 |
| 2 | Integrative Clinical Genomics of Advanced Prostate Cancer Hit paper breakdown → | 2015 | 2985 |
| 3 | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Hit paper breakdown → | 2016 | 2372 |
| 4 | Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Hit paper breakdown → | 2014 | 1961 |
| 5 | Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 1010 |
| 6 | Integrative clinical genomics of metastatic cancer Hit paper breakdown → | 2017 | 687 |
| 7 | Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study Hit paper breakdown → | 2018 | 610 |
| 8 | 2011 | 534 | |
| 9 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 484 |
| 10 | Integrative Clinical Genomics of Advanced Prostate Cancer Hit paper breakdown → | 2015 | 461 |
| 11 | Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab Hit paper breakdown → | 2015 | 382 |
| 12 | Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial Hit paper breakdown → | 2012 | 378 |
| 13 | 2017 | 341 | |
| 14 | 1996 | 339 | |
| 15 | 2018 | 336 | |
| 16 | Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2019 | 331 |
| 17 | 2007 | 321 | |
| 18 | 2007 | 290 | |
| 19 | 2018 | 280 | |
| 20 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma Hit paper breakdown → | 2020 | 276 |
About David C. Smith
David C. Smith is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Surgery and Orthodontics, having authored 358 papers that have together received 37.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (46 papers), Bladder and Urothelial Cancer Treatments (25 papers), Cancer Immunotherapy and Biomarkers (18 papers), Cancer Treatment and Pharmacology (16 papers), Cancer survivorship and care (14 papers), Marine and fisheries research (13 papers), Estrogen and related hormone effects (11 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). The work is most often cited by research in Oncology (18.7k citations), Immunology (7.6k citations), Cancer Research (4.6k citations), Pulmonary and Respiratory Medicine (9.6k citations) and Pathology and Forensic Medicine (1.8k citations). David C. Smith has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Kenneth J. Pienta, Maha Hussain, Marcus D. Ballinger, Daniel S. Chen, Keunchil Park, Achim Rittmeyer, Louis Fehrenbacher, Julien Mazières, Fadi Braiteh and Johan Vansteenkiste. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer, Investigational New Drugs and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.